AQ4N: a new approach to hypoxia-activated cancer chemotherapy

por Patterson, L H, McKeown, S R
Publicado 2000

Formal Appraisal of Junior Medical Staff

por Patterson, L. J., Hajela, V. P.
Publicado 1992

Provision of COVID-19 treatments to non-hospitalised patients in Northern Ireland: an evaluation

por Patterson, L, McGuinness, S, Bradley, D T, Corrigan, D
Publicado 2023

Use of national guidelines for the introduction of Drotrecogin alfa (activated)

por Mackenzie, S, Patterson, L, Plenderleith, L, MacKirdy, F
Publicado 2004

An audit of the use of isolation facilities in a UK National Health Service trust

por Damji, S., Barlow, G.D., Patterson, L., Nathwani, D.
Publicado 2005

Examining the association between socio-demographic factors, catheter use and antibiotic prescribing in Northern Ireland primary care: a cross-sectional multilevel analysis

por Nugent, C., Verlander, N. Q., Varma, S., Bradley, D. T., Patterson, L.
Publicado 2022

Synthesis of a Pseudo-Disaccharide Library and Its Application to the Characterisation of the Heparanase Catalytic Site

por Vinader, Victoria, Haji-Abdullahi, Mohamed H., Patterson, L. H., Afarinkia, Kamyar
Publicado 2013

Comparing the epidemiology of community- and hospital-associated Clostridium difficile infections in Northern Ireland, 2012–2016: a population data linkage and case–case study

por Maisa, A., Ross, G., Verlander, N.Q., Fairley, D., Bradley, D.T., Patterson, L.
Publicado 2019

AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo.

por McKeown, S. R., Hejmadi, M. V., McIntyre, I. A., McAleer, J. J., Patterson, L. H.
Publicado 1995

Prevalence and risk factors associated with Campylobacter spp. and Salmonella enterica in livestock raised on diversified small-scale farms in California

por Pires, A. F. A., Patterson, L., Kukielka, E. A., Aminabadi, P., Navarro-Gonzalez, N., Jay-Russell, M. T.
Publicado 2019

Epidemiology of COVID-19 in Northern Ireland, 26 February 2020–26 April 2020

por Pett, J., McAleavey, P., McGurnaghan, P., Spiers, R., O'Doherty, M., Patterson, L., Johnston, J.
Publicado 2021

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent

por Patterson, L H, McKeown, S R, Ruparelia, K, Double, J A, Bibby, M C, Cole, S, Stratford, I J
Publicado 2000

DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells.

por Hejmadi, M. V., McKeown, S. R., Friery, O. P., McIntyre, I. A., Patterson, L. H., Hirst, D. G.
Publicado 1996

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N

por Gallagher, R, Hughes, C M, Murray, M M, Friery, O P, Patterson, L H, Hirst, D G, McKeown, S R
Publicado 2001

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N

por Gallagher, R, Hughes, C M, Murray, M M, Friery, O P, Patterson, L H, Hirst, D G, McKeown, S R
Publicado 2002

Evidence of a care home effect on antibiotic prescribing for those that transition into a care home: a national data linkage study

por Patterson, L., Maguire, A., Cardwell, C., Kee, F., Hughes, C., Geoghegan, L., Doherty, L., Dolan, M., Verlander, N. Q., O'Reilly, D.
Publicado 2019

Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness

por Cassetti, M Cristina, Pierson, Theodore C, Patterson, L Jean, Bok, Karin, DeRocco, Amanda J, Deschamps, Anne M, Graham, Barney S, Erbelding, Emily J, Fauci, Anthony S
Publicado 2022

Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine

por Friery, O P, Gallagher, R, Murray, M M, Hughes, C M, Galligan, E S, McIntyre, I A, Patterson, L H, Hirst, D G, McKeown, S R
Publicado 2000

Trichloroethylene and its metabolite TaClo lead to degeneration of substantia nigra dopaminergic neurones: Effects in wild type and human A30P mutant α-synuclein mice

por Keane, P.C., Hanson, P.S., Patterson, L., Blain, P.G., Hepplewhite, P., Khundakar, A.A., Judge, S.J., Kahle, P.J., LeBeau, F.E.N., Morris, C.M.
Publicado 2019

The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1

por Potter, G A, Patterson, L H, Wanogho, E, Perry, P J, Butler, P C, Ijaz, T, Ruparelia, K C, Lamb, J H, Farmer, P B, Stanley, L A, Burke, M D
Publicado 2002